RNS Number : 9216T
ValiRx PLC
23 July 2020

VALIRX PLC

("ValiRx", the "Company" or the "Group")

Result of AGM

ValiRx Plc (AIM: VAL) announces that at its Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed.

The proxy votes are set out below:-

Resolutions	For	Against	Discretion
Resolution 1 - Receive the annual report and accounts	4,612,178	0	2,000
Resolution 2 - Re-appoint Gerry Desler as a director	4,226,311	377,739	2,000
Resolution 3 - Re-appoint Dr Suzanne Dilly as a director	4,579,542	23,437	2,000
Resolution 4 - Re-appoint Martin Lampshire as a director	4,579,542	24,623	2,000
Resolution 5 - Re-appoint Dr Kevin Cox as a director	4,580,958	23,207	2,000
Resolution 6 - Re-appoint the auditors	4,573,342	26,058	2,000
Resolution 7 - Set the auditors' remuneration	4,548,033	49,943	2,000
Resolution 8 - Provide authority to allot share capital	4,441,339	62,857	2,008
Resolution 9 - Provide authority to dis-apply statutory pre-emption rights (Special Resolution)	4,436,339	67,857	2,008

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

***** ENDS *****

For more information, please contact:

ValiRx plc **Tel: +44 (0) 20 7073 2628**

www.valirx.com

Suzanne Dilly Suzanne.Dilly@valirx.com

Cairn Financial Advisers LLP (Nominated Adviser) **Tel: +44 (0) 20 7213 0880**

Liam Murray / Jo Turner / Ludovico Lazzaretti

Peterhouse Capital Limited (Sole Broker) **Tel: +44 (0) 20 7469 0930**
Duncan Vasey / Lucy Williams / Eran Zucker

Notes for Editors

About ValiRx

ValiRx PLC accelerates the development of innovative medicines that enhance patient experience. We do this by combining intellectual and financial resources to select, progress and partner a balanced portfolio of risk-reduced, early-stage technologies for translation into clinical candidates.

The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

RAGSEDFFDESSEIW